Cambrex Corporation, a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has announced a commitment to provide its stockholders with additional information regarding its environmental, social and governance (ESG) practices.
Cambrex’s commitment to the environment, health and safety underpins activities across its sites. Over approximately the next 18 to 24 months, Cambrex will develop additional disclosures relating to the company’s ESG related policies, strategies and performance. Once available, stockholders will be able to review these disclosures on Cambrex’s website at www.cambrex.com.
In connection with these announcement, Trillium Asset Management informed Cambrex that it has withdrawn its shareholder proposal requesting the production of an ESG report from the agenda for the upcoming 2018 Annual Meeting of Stockholders. Cambrex said that the company “appreciated Trillium’s perspective on ESG matters and the feedback we received from our investors as part of our shareholder outreach effort”.